Thermo Fisher Scientific Expands Solubility Center of Excellence
Thermo Fisher Scientific is pleased to announce the completion of cGMP facility and equipment investments at its Bend, Oregon facility. The facility, part of the Patheon global CDMO network, now has 4,500 square feet of new ISO 8 manufacturing space, including four new cGMP manufacturing suites, a GEA MOBILE MINORTM spray dryer, and an EKATO SOLIDMIX VPT100 agitated conical vacuum dryer. In addition, the site will add R&D and cGMP Hot Melt Extrusion (HME) capabilities using Thermo Fisher’s Haake MiniCTW and Pharma 11 extruders. This expansion complements the facility’s existing 5,500 square foot, state-of-the-art analytical laboratories, commissioned in 2017. These recent investments, combined with Thermo Fisher’s Quadrant 2TM in silico predictive modeling platform for solubilization technology selection, represent a major addition to the company’s drug solubilization solutions.
“We continue to see strong demand for solubility solutions from our clinical phase customers and Patheon, part of Thermo Fisher Scientific, is committed to offering the broadest array of technical capabilities and expertise,” said Ryan Minikis, Site Leader and Sr. Director of Operations at the company’s Bend facility. “With these investments, combined with our existing clinical-to-commercial scale softgel and HME capabilities and the commercial spray drying investments underway in Florence, South Carolina, we are in a unique position to offer our customers the best technologies, speed and flexibility across all major technology platforms and phases of development.”
Thermo Fisher’s Bend, Oregon, site is the Patheon Center of Excellence for solubilization technology, specializing in spray drying, extrusion and solid dosage form manufacture for clinical trials. The site was founded in 2007 and has offered cGMP manufacturing services since 2011, having supplied drug product to dozens of clinical trials in the US, Europe, Asia and Australia.